Bousingen, D. D. de. (2001). Drug firm compensates patients for suspected hepatitis B vaccine failure. The Lancet, 357(19.05.2001), 1598.
Abstract: A French appeal court has ordered GlaxoSmithKline (GSK) to pay US$6686 and US$10 697 in compensation to two women with multiple sclerosis who claim the chronic disease was caused by a hepatitis B vaccine (Engerix B) manufactured by the pharmaceutical company.
Keywords: health promotion; viral hepatitis; hepatitis B
